Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Fluent Inc
COGT | US
36.68
USD-0.33
-0.89%
COGT | US
Loading StockChartView...
About Fluent Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/03/2026
Close
36.68
Open
36.89
High
38.20
Low
36.34
Cogent Biosciences Inc. a biotechnology company focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486) a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis as well as other mutations in KIT exon 17 which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research development and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences Inc. in October 2020. Cogent Biosciences Inc. was incorporated in 2014 and is headquartered in Waltham Massachusetts.
View LessCOGT | US
Risk
34.1
Sharpe
3.08
Luna's Score
52/100
Recommendation
Hold
Luna says (COGT | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
39.7%1 month
34.1%3 months
45.6%6 months
175.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.92
Debt to equity
0.05
Debt to assets
0.04
Ent. to EBITDA
-3.89
Ent. to rev.
925.41
PEG
-
Other Fundamentals
EBITDA
-242.22M
MarketCap
4.01B
MarketCap(USD)
4.01B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-62.92
Short ratio
8.42
Short perc.
8.40
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
4.92
Range1M
4.95
Range3M
9.32
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.69
Price X volume
43.11M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.89 | 0.53 | Cheaper |
| Ent. to Revenue | 925.41 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.92 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 45.58 | 72.80 | Lower Risk |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 4.01B | 3.66B | Par |
